Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes ...
Q3 2026
May 15, 2026
Q2 2026
Feb 17, 2026
Q1 2026
Nov 14, 2025
FY 2025
Sep 29, 2025
Q4 2025
